Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors

Authors

  • Mar Riveiro-Barciela Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid
  • Didac González-Sans Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain
  • David Marmolejo Oncology Department, Vall d’Hebron Institut of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
  • Maria-Teresa Salcedo Pathology Department, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain
  • Eva Muñoz-Couselo Oncology Department, Vall d’Hebron Institut of Oncology (VHIO), Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain

DOI:

https://doi.org/10.15403/jgld-3207

Keywords:

Immunotherapy, Immune-related adverse events, Sinusoidal obstruction syndrome, Veno-oclusive Disease, Nivolumab

Downloads

Published

2021-03-13

How to Cite

1.
Riveiro-Barciela M, González-Sans D, Marmolejo D, Salcedo M-T, Muñoz-Couselo E. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. JGLD [Internet]. 2021 Mar. 13 [cited 2026 Jan. 14];30(1):171-2. Available from: https://jgld.ro/jgld/index.php/jgld/article/view/3207

Issue

Vol. 30 No. 1: March 2021

Section

Letters